Xcout IntelAlzamend Neuro, Inc.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Subscribe to see Alzamend Neuro, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Alzamend Neuro, Inc. at a glance
Alzamend Neuro, Inc. is a biotech company headquartered in Atlanta, United States. It is publicly listed (ALZN) with a market capitalisation of $4.2M. Xcout tracks 16 named people at Alzamend Neuro, Inc., including Stephan Jackman (Chief Executive Officer & Director).
Alzamend Neuro, Inc. leadership
- Stephan JackmanChief Executive Officer & Director
- William B. HorneChairman of Alzamend, Chief Executive Officer of Ault Alliance, Inc.
- David J. KatzoffChief Financial Officer
- Henry C. W. NisserExecutive Vice President, General Counsel and Director
- Kenneth S CragunSenior Vice President of Finance
- Milton Charles AultFounder & Vice Chairman
10 more named people on record for Alzamend Neuro, Inc., with roles, board committees and tenure — see the full roster →
Alzamend Neuro, Inc. competitors
A few of Alzamend Neuro, Inc.'s closest competitors — see the full list of competitors and alternatives →
Eumentis Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing novel therapies for serious neuropsychiatric conditions.
Synendos Therapeutics is a clinical-stage biopharmaceutical and neuroscience company focused on developing a novel class of small molecules to treat psychiatric and neurological disorders.
ATAI Life Sciences AG is a biopharmaceutical company headquartered in Munich, Germany, focused on acquiring and developing innovative treatments for mental health disorders.
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
Intra-Cellular Therapies was a U.S. biopharmaceutical company focused on developing treatments for central nervous system disorders. Its principal product, CAPLYTA (lumateperone), is used to treat schizophrenia and depressive episodes associated with bipolar disorder in adults, serving patients and mental-healthcare providers.
Get Alzamend Neuro, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Alzamend Neuro, Inc. in Xcout Intel
- 16 named people with titles, LinkedIn and board committees
- 3 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access